poisar

Stocks · News reference

European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application

Vandana Singh

Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PFEVALN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    Freehand CEO Nitin Jayakrishnan Addresses Supply Chain Disruption and Resilience at LogiPharma USA 2026

    Freehand, an AI workforce platform for procurement and accounts payable operations, showcased its solutions at LogiPharma USA 2026. CEO Nitin Jayakrishnan participated in a keynote panel discussing supply chain resilience in the pharmaceutical industry. The company, which serves major healthcare enterprises including Johnson & Johnson and Pfizer, recently raised $75 million in funding to scale its AI Teams that automate complex procurement and spend management processes.

    JNJPFECAH
  2. David Jagielski, Cpa

    Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock

    Eli Lilly, the only healthcare stock in the trillion-dollar club, has rallied 400% over five years driven by its successful GLP-1 drugs Mounjaro and Zepbound. However, with a valuation of 40x trailing earnings and slowing growth prospects, the stock faces significant headwinds from intensifying competition in the GLP-1 market from companies like Pfizer and Viking Therapeutics. The author suggests the stock may have more downside risk than upside potential at current valuations.

    LLYPFEVKTX
  5. Eric Volkman

    Why Pfizer Stock Was so Healthy in August

    Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.

    PFEBNTXVALN